Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here
Pricing and Ordering Information

  

U.S. Markets for Musculoskeletal Tissue Engineering
and Cell Transplantation Products
Report #A422 - July 2010
156 Pages – 24 Exhibits - 12 Company Profiles


This new report from Medtech Insight analyzes the market potential for tissue engineering products for musculoskeletal indications. The United States (U.S.) market for tissue engineering products for musculoskeletal applications is substantial, with many segments representing multibillion-dollar opportunities. In the U.S., the total potential market for these products is expected to exceed $39 billion in the year 2019.

Market segments covered by this report include products for the repair and replacement of bone, cartilage, ligaments, tendons, and menisci. Product categories covered include three-dimensional matrices; autologous cultured chondrocytes; bone grafts and bone substitutes; bone morphogenetic proteins and other growth factors; cartilage regeneration implants; cell-mediated gene therapy; ligament, tendon, meniscal, and other soft tissue repair scaffolds; mesenchymal stem cells; recombinant signaling molecules; and other technology under development, such as radiofrequency and ultraviolet technology for cartilage regeneration.

Also provided are analyses of musculoskeletal tissue-engineered products and competitors and an overview of current biomaterial, cell transplantation, gene therapy, stem cell, and tissue regeneration technologies, along with disease incidence and prevalence figures, a review of existing therapies and treatments, and procedure volumes for the most prevalent musculoskeletal diseases/disorders.

This Medtech Insight report is the second in a series of reports covering U.S. tissue engineering markets. Upcoming reports in this series will provide analyses of U.S. markets for tissue-engineered products for neurologic, organ regeneration, skin replacement, and urologic applications. The first report in this series, #A421, “U.S. Markets for Cardiac and Vascular Tissue Engineering Products,” was published in June 2010.

Ordering Information

Title

 Report# Publication
Date		 List Price

U.S. Markets for Musculoskeletal Tissue Engineering and Cell Transplantation Products

A422

July 2010

$4,750
Order Online:
Single User only (Please call for corporate subscription pricing)		 PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.    Overview

a.   Joint Disorders and Treatments

b.   Bone Disorders and Treatments

ii.    Tissue Engineering Technologies

a.   Biomaterials

b.   Cell Culture Technology

c.   Stem Cell Technology

d.   Immunoisolation Technology

iii.   Tissue Engineering and Cell Transplantation: Musculoskeletal Products Market

a.   Cartilage Repair and Replacement Technologies

b.   Ligament and Tendon Repair and Replacement Technologies

c.   Meniscal Repair and Replacement Technologies

d.   Bone Repair and Replacement Technologies

e.   Market Analysis

iv.   Methodology

 

Exhibit ES-1:    Tissue Engineering Musculoskeletal Products, Potential Market Forecast, 2009 and 2019

 

1. CLINICAL OVERVIEW

1.1 Selected Musculoskeletal Disorders and Existing Therapies

1.1.1 Joint Degeneration

1.1.2 Osteoporosis

1.1.3 Knee Injuries

1.1.3.1 Articular Cartilage Treatments

1.1.3.1.1 Arthroscopy

1.1.3.1.1.1 Procedure Volumes

1.1.3.1.2 Osteochondral Autografting and Cell Implantation

1.1.3.2 Meniscal Injuries

1.1.3.2.1 Meniscal Repair and Meniscectomy Procedure Volumes

1.1.4 Ligament and Tendon Injuries

1.1.4.1 Procedure Volumes

1.1.5 Shoulder Soft Tissue Tears

1.1.5.1 Rotator Cuff Repair

1.1.5.2 Procedure Volumes

1.1.6 Bone Grafts

1.1.6.1 Bone Grafting Materials

1.1.6.1.1 Autografts

1.1.6.1.2 Allografts

1.1.6.1.3 Other Materials

1.1.6.2 Applications

1.1.6.2.1 Fracture Repair

1.1.6.2.2 Total Joint Surgery

1.1.6.2.3 Tumors/Bone Cysts

1.1.6.2.4 Spinal Fusion

1.1.6.2.5 Vertebroplasty

1.1.6.3 Potential Bone Grafting Procedures

 

Exhibit 1-1:      United States Actual and Projected Population, by Age Group, Selected Years, 2000-2050

Exhibit 1-2:      Arthroscopic Knee Surgery, Procedure  Volumes Forecast, 2009-2014

Exhibit 1-3:      Meniscectomy and Meniscal Repair, Procedure Volumes Forecast, 2009-2014

Exhibit 1-4:      2009, Meniscectomy and Meniscal Repair, Procedure Volumes, by Share

Exhibit 1-5:      2009, Ligament and Tendon Repair and Replacement, Procedure Volumes, by Share

Exhibit 1-6:      Arthroscopic and Open Anterior Cruciate Ligament Surgery, Procedure Volumes Forecast, 2009-2014

Exhibit 1-7:      2009, Bone Grafting in Orthopedic/Spine Surgery, Potential Procedure Volumes

 

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

2.1 Biomaterials

2.1.1 Synthetic Biomaterials

2.1.2 Biologically Derived Biomaterials

2.1.2.1 Collagen

2.1.2.2 Xenogeneic Tissue

2.1.3 Hybrid Biomaterials

2.1.4 Genetically Engineered Biomaterials

2.1.4.1 Deoxyribonucleic Acid Transfection Vectors

2.1.4.2 Genetically Manipulated Cells

2.1.4.3 Three-Dimensional Polymer Technology

2.1.4.4 Transgenics

2.1.4.5 Fibroblasts

2.1.4.6 Immortalized Neural Stem Cells

2.1.4.7 Gene-Activated Matrices

2.1.5 Scaffolds

2.1.6 Vascular Grafts

2.2 Cell Culture Technology

2.2.1 Bioreactors

2.2.1.1 Flatbed Perfusion Systems

2.2.1.2 Hollow Fiber Bioreactor Systems

2.2.1.3 Cell Suspension Systems

2.2.1.4 Disposable Bioreactors

2.3 Stem Cell Technology

2.3.1 Cell Extraction and Expansion

2.3.2 Bioreactors

2.4 Immunoisolation Technology

2.4.1 Chimeric Immunity

2.4.2 Cell Encapsulation Technology

 

Exhibit 2-1:      2010, Selected Synthetic Biomaterials Used in Tissue Engineering

Exhibit 2-2:      2010, Selected Natural Biomaterials Used in Tissue Engineering

Exhibit 2-3:      2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies

 

3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: MUSCULOSKELETAL PRODUCTS MARKET

3.1 Cartilage Repair and Replacement

3.1.1 Cell Transplantation Techniques

3.1.1.1 Mesenchymal Stem Cells

3.1.1.1.1 Mesoblast

3.1.1.1.2 Smith & Nephew

3.1.1.2 Autologous Chondrocyte Implantation

3.1.1.2.1 Ars Arthro Biotechnology/Arthro Kinetics

3.1.1.2.2 BioTissue Technologies

3.1.1.2.3 CellCoTec

3.1.1.2.4 DePuy Mitek with Advanced Technologies and Regenerative Medicine/Johnson & Johnson

3.1.1.2.5 Geistlich Surgery/Geistlich Group

3.1.1.2.6 Genzyme Biosurgery/Genzyme

3.1.1.2.7 Histogenics

3.1.1.2.8 ProChon Biotech

3.1.1.2.9 TBF Tissue Engineering

3.1.1.2.10 TiGenix

3.1.1.2.11 Other Companies

3.1.1.3 Allogeneic Juvenile Chondrocytes

3.1.1.4 Allograft Plugs

3.1.1.5 Genetically Altered Cells

3.1.1.5.1 TissueGene

3.1.1.6 Ultraviolet Light

3.2 Ligament and Tendon Repair and Replacement

3.2.1 Bioreactors

3.2.2 Scaffolds

3.2.2.1 Allogeneic

3.2.2.1.1 CryoLife

3.2.2.1.2 LifeCell/Kinetic Concepts

3.2.2.1.3 RTI Biologics

3.2.2.1.4 Wright Medical Technology/Wright Medical Group

3.2.2.2 Xenogeneic

3.2.2.2.1 Cook Biotech/Cook Group

3.2.2.2.2 CryoLife

3.2.2.2.3 DePuy/Johnson & Johnson

3.2.2.2.4 RTI Biologics

3.2.2.3 Collagen

3.2.2.3.1 Collagen Matrix

3.2.2.3.2 Synovis Life Technologies

3.2.2.3.3 TEI Biosciences

3.2.2.3.4 Tornier

3.2.2.3.5 Zimmer

3.2.2.4 Polymeric

3.2.2.4.1 Biomet

3.2.2.4.2 Organogenesis

3.2.2.4.3 Tepha

3.2.3 Growth Factors

3.2.3.1 Biomet Biologics/Biomet

3.2.3.2 Cytomedix

3.2.4 Gene Therapy

3.3 Meniscal Repair and Replacement

3.3.1 Allogeneic Implants

3.3.1.1 RTI Biologics

3.3.2 Collagen Implants

3.3.3 Polymeric Implants

3.3.4 Mesenchymal Stem Cells

3.3.4.1 Osiris Therapeutics

3.3.4.2 University of Pennsylvania

3.4 Bone Repair and Replacement

3.4.1 Biomaterials

3.4.2 Growth Factors

3.4.2.1 Recombinant Growth Factors

3.4.2.2 LIM Mineralization Protein

3.4.2.3 Recombinant Protein UCB-1

3.4.2.3.1 Bone Biologics

3.4.2.3.2 NellOne Therapeutics

3.4.2.4 Bone Morphogenetic Proteins

3.4.2.4.1 Medtronic

3.4.2.4.2 Stryker

3.4.2.4.3 TissueGene

3.4.3 Demineralized Bone Matrix

3.4.3.1 AlloSource

3.4.3.2 Integra LifeSciences

3.4.3.3 Kinetic Concepts

3.4.3.4 Musculoskeletal Transplant Foundation

3.4.3.5 RTI Biologics

3.4.4 Cell Transplantation

3.4.4.1 Autologous Cells

3.4.4.2 Stem Cells

3.4.4.2.1 Aastrom Biosciences

3.4.4.2.2 Alphatec Holdings with Parcell Laboratories

3.4.4.2.3 Cytori Therapeutics

3.4.4.2.4 Mesoblast

3.4.4.2.5 NuVasive

3.4.4.2.6 Orthofix

3.4.5 Gene Therapy

3.4.5.1 Gene Therapy versus Growth Factors

3.4.5.2 Systemic Gene Therapy

3.4.5.3 Regional Gene Therapy

3.4.5.3.1 Tissue Repair Company/Cardium Therapeutics

3.5 Market Analysis

3.5.1 Bone Graft Products Market

3.5.1.1 Allogeneic Demineralized Bone Matrix Products,  Competitive Analysis

3.5.2 Bone Morphogenetic Protein Products Market

3.5.3 Market Drivers

3.5.4 Market Limiters

3.6 Competitive Analysis

 

Exhibit 3-1:      2010, Selected Tissue-Engineered Orthopedic Products

Exhibit 3-2:      2010, Selected Tissue-Engineered Cartilage Repair and Replacement Products

Exhibit 3-3:      2010, Selected Tissue-Engineered Ligament and Tendon Repair and Replacement Products

Exhibit 3-4:      2010, Selected Meniscal Repair and Replacement Products for Tissue Engineering Applications

Exhibit 3-5:      2010, Selected Bone Repair Products for Tissue Engineering Applications

Exhibit 3-6:      2010, Selected Bone Void Fillers/Bone Replacement Materials for Tissue Engineering Applications

Exhibit 3-7:      Comparison of Growth Factors and Gene Therapy for Bone Repair

Exhibit 3-8:      Gene Therapy Delivery Methods for Bone Repair

Exhibit 3-9:      Tissue Engineering Musculoskeletal Products, Potential Market Forecast, 2009 and 2019

Exhibit 3-10:    2009, Bone Grafts and Bone Substitutes Market

Exhibit 3-11:    2009, Allogeneic Demineralized Bone Matrix Products,  Share by Supplier

Exhibit 3-12:    Bone Morphogenetic Protein Products,  Market Forecast, 2009-2014

Exhibit 3-13:    Tissue Engineering Musculoskeletal Products, Product Introduction Forecast, by Indication, 2014 and 2019

 

4. COMPANY PROFILES

4.1       Histogenics Corporation

4.2       Mesoblast LTD

4.3       NuVasive, Inc.

4.4       Osiris Therapeutics, Inc.

4.5       Osteotech, Inc.

4.6       ProChon Biotech LTD

4.7       TBF Tissue Engineering

4.8       TEI Biosciences, Inc.

4.9       Tepha, Inc.

4.10     TiGenix NV

4.11     Wright Medical Group, Inc.

4.12     Zimmer Holdings, Inc.

 

APPENDIX: COMPANY LISTING

To order reports or obtain information about special pre-publication offers from within the U.S., contact reports@elsevier.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home